Genetic and biological hallmarks of colorectal cancer
Colorectal cancer has served as a genetic and biological paradigm for the evolution of solid
tumors, and these insights have illuminated early detection, risk stratification, prevention …
tumors, and these insights have illuminated early detection, risk stratification, prevention …
[HTML][HTML] Colorectal liver metastases: Current management and future perspectives
J Martin, A Petrillo, EC Smyth, N Shaida… - World Journal of …, 2020 - ncbi.nlm.nih.gov
The liver is the commonest site of metastatic disease for patients with colorectal cancer, with
at least 25% developing colorectal liver metastases (CRLM) during the course of their …
at least 25% developing colorectal liver metastases (CRLM) during the course of their …
[HTML][HTML] ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, A Sobrero… - Annals of …, 2016 - Elsevier
Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …
[HTML][HTML] T-cell transfer therapy targeting mutant KRAS in cancer
We identified a polyclonal CD8+ T-cell response against mutant KRAS G12D in tumor-
infiltrating lymphocytes obtained from a patient with metastatic colorectal cancer. We …
infiltrating lymphocytes obtained from a patient with metastatic colorectal cancer. We …
[HTML][HTML] The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy
Colorectal cancer (CRC) results from the progressive accumulation of multiple genetic and
epigenetic aberrations within cells. The progression from colorectal adenoma to carcinoma …
epigenetic aberrations within cells. The progression from colorectal adenoma to carcinoma …
Immunogenicity of somatic mutations in human gastrointestinal cancers
It is unknown whether the human immune system frequently mounts a T cell response
against mutations expressed by common epithelial cancers. Using a next-generation …
against mutations expressed by common epithelial cancers. Using a next-generation …
Detection of circulating tumor DNA in early-and late-stage human malignancies
C Bettegowda, M Sausen, RJ Leary, I Kinde… - Science translational …, 2014 - science.org
The development of noninvasive methods to detect and monitor tumors continues to be a
major challenge in oncology. We used digital polymerase chain reaction–based …
major challenge in oncology. We used digital polymerase chain reaction–based …
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
JY Douillard, KS Oliner, S Siena… - … England Journal of …, 2013 - Mass Medical Soc
Background Patients with metastatic colorectal cancer that harbors KRAS mutations in exon
2 do not benefit from anti–epidermal growth factor receptor (EGFR) therapy. Other activating …
2 do not benefit from anti–epidermal growth factor receptor (EGFR) therapy. Other activating …
PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 …
LS Schwartzberg, F Rivera, M Karthaus… - Journal of clinical …, 2014 - ascopubs.org
Purpose To evaluate panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin
(mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated wild …
(mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated wild …
Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution
The EGFR-targeted antibodies cetuximab and panitumumab are used to treat metastatic
colorectal cancers. Mutations in KRAS, NRAS, and BRAF and amplification of ERBB2 and …
colorectal cancers. Mutations in KRAS, NRAS, and BRAF and amplification of ERBB2 and …